Clevidipine

Generic Name: Clevidipine

Brand Names: Cleviprex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃Cl_₂NO_₆

CAS Number: 167221-71-8

Unique Ingredient Identifier: 19O2GP3B7Q

Background: Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Indication: For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.

Associated Conditions: Hypertension

Associated Therapies: -

Clinical Trials

Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia

Phase 4

Not yet recruiting

Conditions: Hypertension

Interventions: Drug: Lactated Ringers, Intravenous
Drug: Clevidipine

First Posted Date: 2023-10-03

Last Posted Date: 2024-11-08

Lead Sponsor: University of California, San Diego

Target Recruit Count: 64

Registration Number: NCT06063772

Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Phase 3

Completed

Conditions: Stroke, Acute
Blood Pressure
Mechanical Thrombectomy

Interventions: Drug: Clevidipine

First Posted Date: 2022-01-03

Last Posted Date: 2025-01-07

Lead Sponsor: ProMedica Health System

Target Recruit Count: 80

Registration Number: NCT05175547

Locations: 🇺🇸
ProMedica Toledo Hospital, Toledo, Ohio, United States

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

Early Phase 1

Completed

Conditions: Vascular Diseases

Interventions: Other: Increased venous pressure
Drug: Clevidipine
Other: tetanic stimulus
Drug: Phenylephrine
Drug: Dexmedetomidine
Drug: Calcium Chloride

First Posted Date: 2018-10-25

Last Posted Date: 2022-06-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT03719001

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Phase 4

Withdrawn

Conditions: Nontraumatic Intracerebral Hemorrhage, Multiple Localized

Interventions: Drug: Urapidil
Drug: Clevidipine

First Posted Date: 2017-10-03

Last Posted Date: 2021-11-08

Lead Sponsor: University of Zurich

Registration Number: NCT03300479

Locations: 🇨🇭
University Hospital Zurich, Zurich, Switzerland

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

Phase 2

Withdrawn

Conditions: Subarachnoid Hemorrhage
Cerebral Aneurysm
Vasospasm, Intracranial

Interventions: Drug: clevidipine

First Posted Date: 2013-12-13

Last Posted Date: 2023-02-01

Lead Sponsor: Henry Ford Health System

Registration Number: NCT02011321

Locations: 🇺🇸
Henry Ford hospital, Detroit, Michigan, United States

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

Phase 4

Terminated

Conditions: Pediatric Perioperative Blood Pressure Management

Interventions: Drug: clevidipine

First Posted Date: 2013-09-10

Last Posted Date: 2024-05-16

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT01938547

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Stanford Medical Center, Stanford, California, United States

The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: Clevidipine

First Posted Date: 2013-07-29

Last Posted Date: 2013-07-29

Lead Sponsor: Mario Ammirati

Registration Number: NCT01910532

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion

Phase 2

Completed

Conditions: Neuromuscular Scoliosis

Interventions: Drug: Clevidipine

First Posted Date: 2012-07-20

Last Posted Date: 2015-02-18

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 50

Registration Number: NCT01645111

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: clevidipine butyrate

First Posted Date: 2012-02-06

Last Posted Date: 2017-07-17

Lead Sponsor: Columbia University

Registration Number: NCT01526876

Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection

Not Applicable

Withdrawn

Conditions: Aorta Aneurysm
Dissection of Aorta

First Posted Date: 2011-11-29

Last Posted Date: 2013-02-11

Lead Sponsor: Duke University

Registration Number: NCT01480531

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy